US Precision-Medicine Proposal Sparks Questions
By Sara Reardon,
Nature
| 01. 22. 2015
Untitled Document
With the pipeline of traditional drugs drying up, researchers are increasingly attempting to customize treatments based on a person's genetics or environment. Now the US government wants to get in on the act.
During his State of the Union address to Congress on 20 January, President Barack Obama announced a programme called the Precision Medicine Initiative. “I want the country that eliminated polio and mapped the human genome to lead a new era of medicine — one that delivers the right treatment at the right time,” he said.
The White House is remaining tight-lipped about the details of the programme, declining to answer questions from Nature — as is the US National Institutes of Health (NIH), which is expected to be a key partner in the effort. But Kay Holcombe, senior vice-president for science policy at the Biotechnology Industry Organization (BIO) in Washington DC, says that her conversations with the NIH suggest that the agency will seek to match genome information with many other types of data, such as health records and blood-test results.
The agency seems to...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...